Clinical Trials
82 trialsPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
Fox Chase Cancer Center
TARSARC
Institut Bergonié
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
City of Hope Medical Center
ANTARES
Instituto do Cancer do Estado de São Paulo
A Study of Ivonescimab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
PANTHR-S
Royal Marsden NHS Foundation Trust
REGOSTA
Centre Leon Berard
Localized Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
DAPPER
University Health Network, Toronto
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
PROSARC-1
Oslo University Hospital
PROSARC-2
Oslo University Hospital
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
Northwestern University
TAIS
Fudan University
Metastatic Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
PEMBROSARC
Institut Bergonié
LEADER
National Taiwan University Hospital
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Memorial Sloan Kettering Cancer Center
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
University of Utah
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
SAMHY2
Institut Claudius Regaud
CoRDS
Sanford Health
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
APX005M and Doxorubicin in Advanced Sarcoma
Columbia University
TAGGED
Sarcoma Oncology Research Center, LLC
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
ALCI2
Children's National Research Institute
PazoDoble
North Eastern German Society of Gynaecological Oncology
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
MYSTR
Charles University, Czech Republic
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Fred Hutchinson Cancer Center
CERTUM
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ATX-101
Columbia University
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Niraparib for the Treatment of Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
M6620 (VX-970) in Selected Solid Tumors
Massachusetts General Hospital
TRASTS
Grupo Espanol de Investigacion en Sarcomas
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Masonic Cancer Center, University of Minnesota
Patient Reported Outcome Measures (PROMs) With Trabectedin
University of Leeds
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Fred Hutchinson Cancer Center
SAMHY SARCOME
Institut Claudius Regaud
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute